Prototyping Trastuzumab Docetaxel Immunoliposomes with a New FCM-Based Method to Quantify Optimal Antibody Density on Nanoparticles

Developing targeted nanoparticles is a rising strategy to improve drug delivery in oncology. Antibodies are the most commonly used targeting agents. However, determination of their optimal number at the surface remains a challenging issue, mainly due to the difficulties in measuring precisely surfac...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodallec, A., Franco, C., Robert, S., Sicard, G., Giacometti, S., Lacarelle, B., Bouquet, F., Savina, A., Lacroix, R., Dignat-George, F., Ciccolini, J., Poncelet, P., Fanciullino, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057981/
https://www.ncbi.nlm.nih.gov/pubmed/32139753
http://dx.doi.org/10.1038/s41598-020-60856-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057981/
https://www.ncbi.nlm.nih.gov/pubmed/32139753
http://dx.doi.org/10.1038/s41598-020-60856-z

Ejemplares similares